It has been demonstrated that miR-124 exerts its anti-tumor effects via targeting SphK1 in osteosarcoma, melanoma, head, and neck squamous cell carcinoma, and ovarian cancer [153–156]. This evidence concerns the gene SPHK1 and ovarian carcinoma.